NDLI: Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients.

Please wait, while we are loading the content...

Rapid decreases in blood pressure from antihypertensive treatment were associated with increased cancer mortality in the Systolic Hypertension in the Elderly Program.

Pooling prospective studies to investigate the etiology of second cancers.

Decline in physical activity level in the Childhood Cancer Survivor Study cohort.

Use of multiple imputation to correct for bias in lung cancer incidence trends by histologic subtype.

Effects of physical activity on melatonin levels in previously sedentary men and women.

Salivary auto-antibodies as noninvasive diagnostic markers of oral cavity squamous cell carcinoma.

Validating self-reported mammography use in vulnerable communities: findings and recommendations.

Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure.

Dietary insulin index and insulin load in relation to endometrial cancer risk in the Nurses' Health Study.

PLCE1 mRNA and protein expression and survival of patients with esophageal squamous cell carcinoma and gastric adenocarcinoma.

C-reactive protein and colorectal cancer mortality in U.S. adults.

Time to screening in the systems of support to increase colorectal cancer screening trial.

Recent BRCAPRO upgrades significantly improve calibration.

Family history of colorectal cancer is not associated with colorectal cancer survival regardless of microsatellite instability status.

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients.

Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: a prospective study in taiwan.

Risk prediction models for melanoma: a systematic review.

Predicted 25(OH)D score and colorectal cancer risk according to vitamin D receptor expression.

Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer.

Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).

Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial.

Year: 2014 Volume: 23 Issue: 7

Year: 2014 Volume: 23 Issue: 6

Year: 2014 Volume: 23 Issue: 5

Year: 2014 Volume: 23 Issue: 4

Year: 2014 Volume: 23 Issue: 3

Year: 2014 Volume: 23 Issue: 2

Year: 2014 Volume: 23 Issue: 1

Year: 2013 Volume: 22

Year: 2012 Volume: 21

Year: 2011 Volume: 20

Year: 2010 Volume: 19

Year: 2009 Volume: 18

Year: 2008 Volume: 17

Year: 2007 Volume: 16

Year: 2006 Volume: 15

Year: 2005 Volume: 14

Year: 2004 Volume: 13

Year: 2003 Volume: 12

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Levin, Albert M. Lindquist, Karla J. Avila, Andrew Witte, John S. Paris, Pamela L. Rybicki, Benjamin A.
Description	Author Affiliation: Levin AM ( Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan); Lindquist KJ ( Department of Epidemiology and Biostatistics); Avila A ( Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.); Witte JS ( Department of Epidemiology and Biostatistics); Paris PL ( Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California brybick1@hfhs.org pparis@cc.ucsf.edu.); Rybicki BA ( Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan)
Abstract	Evaluation of prostate cancer prognosis after surgery is increasingly relying upon genomic analyses of tumor DNA. We assessed the ability of the biomarker panel Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) to predict biochemical recurrence in 33 European American and 28 African American prostate cancer cases using genome-wide copy number data from a previous study. 'Biomarker positive' was defined as ≥20% of the 38 constituent copy number gain/loss GEMCaP loci affected in a given tumor; based on this threshold, the frequency of a positive biomarker was significantly lower in African Americans (n = 2; 7%) than European Americans (n = 11; 33%; P = 0.013). GEMCaP positivity was associated with risk of recurrence [hazard ratio (HR), 5.92; 95% confidence interval (CI), 2.32-15.11; P = 3 × 10(-4)] in the full sample and among European Americans (HR, 3.45; 95% CI, 1.13-10.51; P = 0.032) but was not estimable in African Americans due to the low rate of GEMCaP positivity. Overall, the GEMCaP recurrence positive predictive value (PPV) was 85%; in African Americans, PPV was 100%. When we expanded the definition of loss to include copy-neutral loss of heterozygosity (i.e., loss of one allele with concomitant duplication of the other), recurrence PPV was 83% for European American subjects. Under this definition, 5 African American subjects had a positive GEMCaP test value; 4 went on to develop biochemical recurrence (PPV = 80%). Our results suggest that the GEMCaP biomarker set could be an effective predictor for both European American and African American men diagnosed with localized prostate cancer who may benefit from immediate aggressive therapy after radical prostatectomy.
File Format	HTM / HTML
ISSN	10559965
e-ISSN	15387755
DOI	10.1158/1055-9965.EPI-13-1124
Journal	Cancer Epidemiology Biomarkers & Prevention
Issue Number	8
Volume Number	23
Language	English
Publisher	American Association for Cancer Research
Publisher Date	2014-08-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Cancer epidemiology Neoplasm Recurrence, Local Diagnosis Genetics Prostatic Neoplasms African Americans Tumor Markers, Biological Gene Dosage Genomics Neoplasm Metastasis Polymorphism, Single Nucleotide Prognosis Research Support, N.i.h., Extramural
Content Type	Text
Resource Type	Article
Subject	Epidemiology Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) Tumor Biomarker for Identifying Recurrent Disease in African American Patients

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) Tumor Biomarker for Identifying Recurrent Disease in African American Patients

Relationship of early-onset baldness to prostate cancer in African-American men.

Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection.

Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment.

Serum creatinine and prostate cancer risk in a prospective study.

A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.

Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer.

Cyr61 is a potential prognostic marker for prostate cancer.

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients.

Similar Documents

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) Tumor Biomarker for Identifying Recurrent Disease in African American Patients

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) Tumor Biomarker for Identifying Recurrent Disease in African American Patients

Relationship of early-onset baldness to prostate cancer in African-American men.

Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection.

Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment.

Serum creatinine and prostate cancer risk in a prospective study.

A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.

Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer.

Cyr61 is a potential prognostic marker for prostate cancer.

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients.